Hunan Warrant Pharmaceutical (SHA:688799) subsidiary Hunan Warrant Chiral Drugs passed the U.S. Food and Drug Administration's on-site inspection for its pantoprazole sodium active pharmaceutical ingredient.
The product is used to manufacture treatments for active peptic ulcers, reflux esophagitis, and Zollinger-Ellison syndrome, according to a Saturday filing with the Shanghai bourse.